Use of ΔIVC for Early Diagnosis of AHF in AECOPD

NCT ID: NCT05327374

Last Updated: 2023-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

401 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-01

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute Heart failure (AHF) is a common cause of acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

This association is frequently underestimated with regard to the difficulty of clinical diagnosis.

The investigators expect that the application of the inferior vena cava collapsibility index (ΔIVC)could be useful in this issue.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute heart failure (AHF) is a common cause of COPD exacerbation however its role is very often underestimated. Until now, the use of echocardiography and some invasive hemodynamic exploration techniques such as the Swanganz catheter has been stated as reference. Other noninvasive diagnostic methods have been studied, such as systolic time intervals and Valsalva maneuver, but their application still difficult in patients with COPD exacerbation, especially in emergency department (ED) settings. the study aimed to evaluate the performance of a new diagnostic technique based on the measurement of the ΔIVC for the early identification of AHF in patients presenting to the ED with acute COPD exacerbation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Decompensated Heart Failure COPD Exacerbation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AHF-group

patients with AECOPD and acute heart failure

calculation of the inferior vena cava collapsibility index

Intervention Type DIAGNOSTIC_TEST

the ΔIVC was calculated by the emergency physician who was blinded from the patient's medical history using the formula ((IVCmax-IVCmin)/IVCmax) X100.A cutoff of 15% was used to define the presence(\<15%) or absence(\>15%) of heart failure

non AHF-group

patients with AECOPD without acute heart failure

calculation of the inferior vena cava collapsibility index

Intervention Type DIAGNOSTIC_TEST

the ΔIVC was calculated by the emergency physician who was blinded from the patient's medical history using the formula ((IVCmax-IVCmin)/IVCmax) X100.A cutoff of 15% was used to define the presence(\<15%) or absence(\>15%) of heart failure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

calculation of the inferior vena cava collapsibility index

the ΔIVC was calculated by the emergency physician who was blinded from the patient's medical history using the formula ((IVCmax-IVCmin)/IVCmax) X100.A cutoff of 15% was used to define the presence(\<15%) or absence(\>15%) of heart failure

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient with history of COPD and admitted to the emergency departement for AECOPD

Exclusion Criteria

* impossibility to give consent to participate in the study, non consent patients
* post traumatic dyspnea
* instable hemodynamic or neurological status
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Monastir

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pr. Semir Nouira

professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nouira Semir, Professor

Role: PRINCIPAL_INVESTIGATOR

University of Monastir

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Fattouma Bourguiba

Monastir, , Tunisia

Site Status

Emergency Departement

Monastir, , Tunisia

Site Status

Emergency department of fattouma bourguiba university hospital

Monastir, , Tunisia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Tunisia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ΔIVC /AHF/ AECOPD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.